within Pharmacolibrary.Drugs.ATC.B;

model B01AB02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 6.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 3000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.047,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.03,
    k12             = 4.7,
    k21             = 4.7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AB02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Antithrombin III is a naturally occurring inhibitor of several coagulation enzymes, primarily thrombin and factor Xa. It is used therapeutically as a replacement therapy in patients with hereditary or acquired antithrombin deficiency, often to prevent thromboembolic events during high-risk procedures. Antithrombin III (human plasma-derived or recombinant) is approved and used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adults and patients with hereditary antithrombin deficiency; administered as intravenous bolus or infusion.</p><h4>References</h4><ol><li><p>Kim, KA, et al., &amp; Park, JY (2013). Bioequivalence of two intravenous formulations of antithrombin III: a two-way crossover study in healthy Korean subjects. <i>Clinical therapeutics</i> 35(11) 1752–1761. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2013.08.018&quot;>10.1016/j.clinthera.2013.08.018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24094463/&quot;>https://pubmed.ncbi.nlm.nih.gov/24094463</a></p></li><li><p>Marzo, A, et al., &amp; Parenti, M (2002). Pharmacokinetic behaviour of antithrombin III following intravenous infusion in healthy volunteers. <i>Arzneimittel-Forschung</i> 52(3) 187–193. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1299878&quot;>10.1055/s-0031-1299878</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11963646/&quot;>https://pubmed.ncbi.nlm.nih.gov/11963646</a></p></li><li><p>Moffett, BS, et al., &amp; Yee, DL (2017). Population pharmacokinetics of human antithrombin concentrate in paediatric patients. <i>British journal of clinical pharmacology</i> 83(11) 2450–2457. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13359&quot;>10.1111/bcp.13359</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28664670/&quot;>https://pubmed.ncbi.nlm.nih.gov/28664670</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AB02;
